Last reviewed · How we verify
NCT04550702
Predictors for Retreatement of OAB After DC Mirabegron
trial testing Mirabegron 25mg in Recurrence of Overactive Bladder Syndrome in 120 participants. Completed in 31 July 2019.
31 July 2019
Quick facts
| Lead sponsor | National Taiwan University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 120 |
| Start date | 1 January 2015 |
| Primary completion | 31 July 2019 |
| Estimated completion | 31 July 2019 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Mirabegron 25mg — full drug profile →
Conditions studied
- Recurrence of Overactive Bladder Syndrome — all drugs for Recurrence of Overactive Bladder Syndrome →
Sponsor
National Taiwan University Hospital
Who can join
Adults 20 to 85, female only, with Recurrence of Overactive Bladder Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Recurrence of female overactive bladder syndrome (OAB) is not uncommon. It is important to decrease the recurrence of female OAB. However, factors predicting recurrence of female OAB, especially for those women who need retreatment is undetermined. Thus, the aim of this study was to elucidate factors predicting retreatment of female OAB.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04550702
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mirabegron 25mg
Trials testing the same drug.
- NCT07114640 — The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Func · Phase 3 · not yet recruiting
- NCT05040984 — Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome · unknown
- NCT03695822 — Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndro · Phase 4 · withdrawn
- NCT03558919 — Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder · Phase 4 · completed
- NCT03059134 — Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan · Phase 3 · completed
Other National Taiwan University Hospital trials
Trials by the same sponsor.
- NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
- NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
- NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
- NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
- NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04550702 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
- Last refreshed: 16 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04550702.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing